Citadel Advisors
PROK icon

Citadel Advisors’s ProKidney PROK Stock Holding History

Citadel Advisors’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,500
Closed -$34.7K – 13967
2025
Q4 		$34.7K Sell
15,500
-29,800
-66% -$78.4K ﹤0.01% 12170
2025
Q3 		$110K Buy
+45,300
New +$121K ﹤0.01% 11785
2025
Q2 		– Sell
-7,300
Closed -$6.4K – 14539
2025
Q1 		$6.4K Sell
7,300
-9,100
-55% -$12.6K ﹤0.01% 13759
2024
Q4 		$27.7K Sell
16,400
-10,500
-39% -$18.9K ﹤0.01% 12941
2024
Q3 		$51.6K Buy
26,900
+9,300
+53% +$21.1K ﹤0.01% 11871
2024
Q2 		$43.3K Buy
17,600
+11,500
+189% +$30.9K ﹤0.01% 11921
2024
Q1 		$10K Buy
6,100
+2,100
+53% +$3.08K ﹤0.01% 13475
2023
Q4 		$7.12K Buy
+4,000
New +$8.58K ﹤0.01% 13311
2023
Q3 		– Sell
-700
Closed -$7.83K – 14921
2023
Q2 		$7.83K Buy
+700
New +$7.45K ﹤0.01% 13352

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's PROK Position: Q1 2026 in Review

Citadel Advisors sold out of ProKidney (PROK) in Q1 2026, closing a stake of 371,797 shares — an estimated $789K sold.

Citadel Advisors first reported a position in PROK in Q2 2021 and held it in 11 quarters. The position peaked at $11.3M in Q1 2022. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Citadel Advisors reported no remaining ProKidney position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 371,797 ProKidney shares in Q1 2026, an estimated $789K.
  • Citadel Advisors first reported a position in ProKidney in Q2 2021 and held it in 11 quarters.
  • Citadel Advisors's ProKidney position peaked at $11.3M in Q1 2022.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.